It’s clear. R&D budgets are tightening in many industries, ranging from automotive to biopharma and universities. In academia, for instance, there is an at least $11 billion federal research funding freeze while some automotive companies and suppliers trimming thousands of R&D positions and broader research investments. Although biopharma R&D efficiency has ticked up, the overall drug approval odds have fallen to 6.7% from 10% a decade ago. But at the same time, new cost‑saving technologies are emerging that make discovery more capital‑efficient and data‑driven.
To learn more, download this R&D World e-book.
Sponsored By:
"*" indicates required fields
By clicking 'Submit' above and registering for this content, I acknowledge and agree to WTWH Media's Terms and Conditions and to WTWH Media's use of my contact information to communicate with me about offerings by WTWH Media, its brands, affiliates and/or third-party partners, consistent with WTWH Media's Privacy Policy. In addition, I understand that my personal information may be shared with any sponsor(s) of the content, and that they may contact me directly about their products or services. Please refer to the privacy policies of such sponsor(s) for more details on how your information will be used by them.
